肿瘤防治研究2024，Vol.51Issue(7)：542-545,4.DOI:10.3971/j.issn.1000-8578.2024.24.0040
2023年FDA批准的癌症治疗药物进展
Development on Cancer Therapeutic Drugs Approved by FDA in 2023
黄青 1薛畅 1胡胜2
作者信息
- 1. 430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院淋巴瘤内科
- 2. 430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院胸部肿瘤内科
- 折叠
摘要
Abstract
Since the beginning of the 21st century,the field of cancer drug development has undergone significant changes.Kinase inhibitors are the product category with the highest number of approved drugs and indications.However,despite checkpoint inhibitors being only introduced to the market since 2011,they have become the second most approved product categories.In the year of 2023,the FDA's Center for Drug Evaluation and Research(CDER)has approved 13 new cancer therapeutic drugs.In the past five years,a slight increase in drug approvals targeting biomarker-defined populations as well as emerging approvals that are agnostic to tumor anatomy has been recorded.Currently,new treatment approaches and technologies,such as the development of Artificial Intelligence(AI),have increasingly profound progress on cancer drug development.关键词
癌症/药物开发/免疫治疗/靶向治疗/生物制剂Key words
Cancer/Drug development/Immunotherapy/Targeted therapy/Biologics分类
医药卫生引用本文复制引用
黄青,薛畅,胡胜..2023年FDA批准的癌症治疗药物进展[J].肿瘤防治研究,2024,51(7):542-545,4.
